文献速递疝与腹壁外科围术期管理与 ERAS

新型生物合成补片在高风险腹壁疝修补中降低复发率

A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients.
PubMed 文献 · Surg Endosc · 2020-09-24

该回顾性研究比较了50例使用OviTex生物合成补片与50例使用合成补片行腹壁疝修补的高风险患者,随访12个月。OviTex组VHWG 3级和CDC伤口污染 class > I比例更高,但两组手术部位事件、再入院和疝复发率无显著差异;发生手术部位事件的患者中,OviTex组疝复发率显著低于合成补片组。

要点

  • 高风险腹壁疝患者使用OviTex生物合成补片安全可行,12个月复发率与合成补片相当。
  • 发生手术部位事件时,OviTex组疝复发率显著低于合成补片组(17% vs 55%)。
  • OviTex组患者基线风险更高(VHWG 3级68%,CDC class > I 70%),仍获得可比结果。

核心结论

  • OviTex生物合成补片用于高风险腹壁疝修补,手术部位事件、再入院和疝复发率与合成补片相似。
  • 发生手术部位事件的患者中,OviTex组疝复发率显著低于合成补片组。
  • 数据提示生物合成补片是高危患者确定性疝修补的更理想选择。

研究设计与样本

  • 回顾性比较两个连续50例队列,分别使用TELA Bio OviTex生物合成补片或合成补片行腹壁疝修补。
  • 评估术后12个月的手术部位事件、再入院率和疝复发。

主要发现

  • OviTex组VHWG 3级比例68% vs 合成补片组6%(p < 0.001),CDC伤口 class > I比例70% vs 6%(p < 0.001)。
  • OviTex组同期手术比例70% vs 10%(p < 0.001)。
  • 手术部位事件发生率36% vs 22%(p = 0.19),再入院率24% vs 14%(p = 0.31),疝复发率6% vs 12%(p = 0.74)。
  • 发生手术部位事件者中,OviTex组(n=18)疝复发率17%,合成补片组(n=11)55%(p = 0.048)。

关键数值与推荐

  • 高风险定义包括VHWG分级和CDC伤口分类,OviTex组分布更高。
  • 疝复发评估时间为术后12个月。

临床怎么用

  • 对于术后感染风险较高的腹壁疝患者,可考虑使用OviTex生物合成补片。
  • 即使发生手术部位事件,生物合成补片可能降低后续疝复发风险。

局限性

  • 回顾性设计,样本量小(每组50例)。
  • 两组基线风险不一致,存在选择偏倚。
  • 随访时间仅12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with higher postoperative infection risk undergoing ventral hernia repair (VHR) have limited options for mesh use. Biosynthetic mesh is intended to utilize the durability of synthetic mesh combined with the biocompatibility of biologic mesh. We sought to assess the outcomes of a novel biosynthetic scaffold mesh for VHR in higher risk patients over a 12-month postoperative period. METHODS: Two cohorts of 50 consecutive patients who underwent VHR with TELA Bio OviTex biosynthetic or synthetic mesh were retrospectively compared. Endpoints included surgical site occurrence (SSO), readmission rate, and hernia recurrence following VHR at 12 months postoperatively. RESULTS: OviTex mesh placement was associated with higher risk Ventral Hernia Working Group (VHWG) distribution and more contaminated CDC wound class distribution compared to synthetic mesh placement (VHWG grade 3: 68% vs. 6%, p < 0.001; CDC class > I: 70% vs. 6%, p < 0.001). Additionally, concomitant procedures were performed more often with OviTex mesh placement than synthetic mesh placement (70% vs 10%, p < 0.001). The OviTex mesh performed comparably to synthetic mesh in terms of incidences of SSO (36% vs 22%, p = 0.19), readmission rates (24% vs 14%, p = 0.31), and hernia recurrence (6% vs 12%, p = 0.74). On further evaluation, patients who developed SSO with OviTex mesh (n = 18) had a 17% hernia recurrence whereas those with synthetic mesh (n = 11) had an associated 55% hernia recurrence (p = 0.048). CONCLUSIONS: The OviTex biosynthetic mesh was used in higher risk patients and performed similarly to synthetic mesh in regards to rate of SSO, readmissions, and hernia recurrence. Furthermore, patients who developed SSO with Ovitex mesh were significantly less likely to have hernia recurrence than those with synthetic mesh. Overall, the data suggest that biosynthetic mesh is a more desirable option for definitive hernia repair in higher risk patients.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Parker MJ, Kim RC, Barrio M, et al. A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients. Surg Endosc. 2020. PMID: 32970208. doi:10.1007/s00464-020-08009-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。